<DOC>
	<DOCNO>NCT03060447</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability 10-dose regimen GS-9620 HIV-1 infect controller antiretroviral treatment ( ART ) analytical treatment interruption ( ATI ) follow GS-9620 dosing .</brief_summary>
	<brief_title>Evaluate Safety Efficacy GS-9620 Antiretroviral Treated HIV-1 Infected Controllers</brief_title>
	<detailed_description />
	<criteria>Key Plasma HIV1 RNA level &lt; 50 copies/mL screen PreART Plasma HIV1 RNA set point 50 ≤ 5,000 copies/mL measure within two year prior ART initiation On ART ≥ 6 month prior screen Documented plasma HIV1 RNA &lt; 50 copies/mL ≥ 6 month precede screen visit ( undetectable HIV1 RNA level accord local assay use limit detection ≥ 50 copies/mL ) . Unconfirmed virologic elevation ≥ 50 copies/mL ( transient detectable viremia , `` blip '' ) prior screen acceptable . No documented history resistance component current ART regimen Availability fully active alternative ART regimen , opinion Investigator , event discontinuation current ART regimen development resistance . Hemoglobin ≥ 11.5 g/dL ( male ) ≥ 11 g/dL ( female ) White Blood Cells ≥ 2,500 cells/μL Platelets ≥ 125,000/mL Absolute Neutrophil Counts ≥ 1000 cells/μL CD4+ count ≥ 500 cells/μL Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) bilirubin ≤ 2 × upper limit normal ( ULN ) Estimated glomerular filtration rate ≥ 60 mL/min No autoimmune disease require ongoing immunosuppression No evidence current hepatitis B virus ( HBV ) infection No evidence current hepatitis C virus ( HCV ) infection ( positive antiHCV antibody negative HCV polymerase chain reaction ( PCR ) result acceptable ) No documented history preART CD4 nadir &lt; 200 cells/μL ( unknown preART CD4 nadir acceptable ) No history opportunistic illness indicative stage 3 HIV No acute febrile illness within 35 day prior PreBaseline/ Day 13 Note : Other protocl define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>